Velmanase alfa is a recombinant form of human alpha-mannosidase intended to provide or supplement natural alpha-mannosidase. The Food and Drug Administration (FDA) has accepted for Priority Review the ...

Credit: Shutterstock. Velmanase alfa is a recombinant form of human lysosomal alpha-mannosidase intended to provide or supplement natural alpha-mannosidase. The Food and Drug Administration (FDA) has ...

Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the MAN2B1 gene leading to insufficient activity of the enzyme alpha-mannosidase. The resultant ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Lamzede, an enzyme replacement therapy for non-central nervous system manifestations of ...

The FDA approved the enzyme replacement therapy velmanase alfa (Lamzede) for alpha-mannosidosis, developer Chiesi Global Rare Diseases announced on Thursday. Approved as a 10 mg weekly injection, ...

Doctors say the chance of a diagnosis is one in 1,000,000. It’s called Alpha-mannosidosis and two families, far from home, are in Minnesota so their daughters can receive care for the rare disorder — ...

BOSTON, Feb. 16, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today ...

Chiesi Farmaceutici SpA scored U.S. FDA clearance of the enzyme replacement therapy (ERT) Lamzede (velmanase alfa-tycv) for non-central nervous system manifestations of alpha-mannosidosis (AM) in ...

Results presented focus on clinical insights on Fabry disease and alpha-mannosidosis Additional presentations showcase patient-reported journeys and outcomes PARMA, Italy, Sept. 09, 2025 (GLOBE ...

Chiesi Farmaceutici SpA scored U.S. FDA clearance of the enzyme replacement therapy (ERT) Lamzede (velmanase alfa-tycv) for non-central nervous system manifestations of alpha-mannosidosis (AM) in ...